Date: 2016-05-10
Type of information: Nomination
Compound:
Company: Confo Therapeutics (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 10, 2016, Confo Therapeutics, an emerging drug discovery company, announced that Dr. Christel Menet is joining the company as Chief Scientific Officer, effective now. Dr. Menet will lead the research activities and build Confo Therapeutics’ pipeline of development programs targeting G protein-coupled receptors (GPCRs) that are currently considered undruggable for a wide range of conditions. With the appointment of Dr. Menet, Prof. Jan Steyaert, Scientific Founder, will serve as Chairman of the Scientific Advisory Board and continues to remain closely involved with the company. Prof. Steyaert’s breakthrough discoveries on GPCRs at VIB and Vrije Universiteit Brussel are the building blocks of Confo Therapeutics, generating new treatment methods for a wide range of disease conditions that are hard to treat or even untreatable.
Dr. Menet joins Confo Therapeutics from Galapagos, where she advanced through positions of increasing responsibilities, most recently as Director of Chemistry. Dr. Menet is the inventor of filgotinib, Galapagos’ lead program currently in phase III, and was responsible for its full discovery track. Dr. Menet received a Chemical Engineering degree at Ecole Nationale Supérieure de Chimie de Montpellier, France and obtained a PhD in chemistry at the University of Manchester, UK.
Financial terms:
Latest news:
